Integrating predictive biomarkers and classifiers into oncology clinical development programmes
- 30 September 2011
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 10 (10) , 735-748
Abstract
The future of drug development in oncology lies in identifying subsets of patients who will benefit from particular therapies, using predictive biomarkers. These technologies offer hope of enhancing the value of cancer medicines and reducing the size, cost and failure rates of clinical trials. However, examples of the failure of predictive biomarkers also exist. In these cases the use of biomarkers increased the costs, complexity and duration of clinical trials, and narrowed the treated population unnecessarily. Here, we present methods to adaptively integrate predictive biomarkers into clinical programmes in a data-driven manner, wherein these biomarkers are emphasized in exact proportion to the evidence supporting their clinical predictive value. The resulting programme demands value from predictive biomarkers and is designed to optimally harvest this value for oncology drug development.Keywords
This publication has 43 references indexed in Scilit:
- Sources of Bias in Specimens for Research About Molecular Markers for CancerJournal of Clinical Oncology, 2010
- The Cross-Validated Adaptive Signature DesignClinical Cancer Research, 2010
- Randomized Clinical Trials With Biomarkers: Design IssuesJNCI: Journal of the National Cancer Institute, 2010
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- A Comparison of Phase II Study StrategiesClinical Cancer Research, 2009
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsNew England Journal of Medicine, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Clonogenic assay with established human tumour xenograftsEuropean Journal of Cancer, 2004